Primary care physicians, Family medicine practitioners, Nurse practitioners
Opioid Risk Evaluation and Mitigation Strategy, Opioid REMS
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
*To claim and receive MOC credits, learners must email firstname.lastname@example.org and provide (a) ABIM ID number, (b) first and last name, (c) degree and specialty, (d) DOB (month and day), and (e) activity completion date.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is .25 contact hours. Designated for .25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Michael R. Clark, MD, MPH, MBA: no disclosures
Yvonne D’Arcy, MS, ARNP-C, CNS, FAANP has received royalties from Springer Publishing, and honoraris from GlaxoSmithKline, Pfizer, Salix Pharmaceuticals and Ortho-McNeil Pharmaceuticals.
Planners and Managers
The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
|Supported Phones & Tablets: |
Android 4.0.3 and above